Krystal Biotech, Inc. (NASDAQ:KRYS) Stake Trimmed by Redmile Group LLC

Redmile Group LLC lowered its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 20.6% during the third quarter, HoldingsChannel reports. The firm owned 810,245 shares of the company’s stock after selling 210,833 shares during the period. Krystal Biotech comprises 8.7% of Redmile Group LLC’s holdings, making the stock its biggest position. Redmile Group LLC’s holdings in Krystal Biotech were worth $147,489,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in KRYS. GAMMA Investing LLC raised its holdings in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after acquiring an additional 93 shares during the period. Jamison Private Wealth Management Inc. acquired a new stake in shares of Krystal Biotech during the 2nd quarter worth about $28,000. AlphaMark Advisors LLC acquired a new stake in shares of Krystal Biotech during the 2nd quarter worth about $353,000. Blue Trust Inc. increased its position in shares of Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares during the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of Krystal Biotech by 11.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after purchasing an additional 94 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on KRYS shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Stifel Nicolaus raised their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Evercore ISI lifted their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Tuesday, November 5th. Finally, Citigroup lifted their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Krystal Biotech presently has a consensus rating of “Buy” and an average target price of $202.29.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The trade was a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 14.10% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $187.62 on Thursday. Krystal Biotech, Inc. has a one year low of $100.98 and a one year high of $219.34. The company has a market cap of $5.40 billion, a PE ratio of 106.00 and a beta of 0.80. The business has a 50-day simple moving average of $181.08 and a 200-day simple moving average of $184.29.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period in the previous year, the company posted ($0.67) earnings per share. The business’s revenue for the quarter was up 879.9% on a year-over-year basis. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).